NCT01535664 - An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

May 31, 2012

Study Completion Date

June 30, 2012

Conditions

Multiple Sclerosis

Interventions

OTHER

Withdrawal of dalfampridine-ER 10mg

"Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)~* On drug Day-7 (visit 1) through Day 1 (visit 2)~* Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)~* On drug Day 15±2 days (visit 5)"

Trial Locations (1)

73104

OMRF Multiple Sclerosis Center of Excellence, Oklahoma City